Research Fellow and Lecturer in Law
Research Fellow & Lecturer in Law Kate Greenwood researches and writes on a variety of health and pharmaceutical law topics, including prescription drug regulation, prescription drug and medical device litigation and liability, and health care finance, with a particular focus on the Affordable Care Act’s private health insurance reforms. Her current projects include a Robert Wood Johnson Foundation-funded evaluation of the degree to which individuals with marketplace plans in New Jersey are able to access the “essential health benefits” that the Affordable Care Act guarantees. She also supervises law students writing research papers on health and pharmaceutical law topics and teaches and develops content for Seton Hall Law’s Graduate Certificate courses on pharmaceutical and medical device compliance.
Kate serves as Faculty Editor of Health Reform Watch, the blog of Seton Hall Law’s Center for Health & Pharmaceutical Law & Policy. Health Reform Watch features analysis and commentary from Seton Hall’s health law faculty and Recommended Reading posts highlighting the health law scholarship they have been reading and enjoying. It also includes contributions from the students in Seton Hall’s health law program, as well as announcements of program activities. In addition, Kate provides legal commentary to the media, including CNNMoney, Inside Counsel, Pharmaceutical Compliance Monitor, Pharmalot, and the television show American Law Journal, which airs on the Philadelphia-area CNN affiliate.
In 2009, Kate was one of four early-career health law scholars selected to present at the annual Health Law Scholars Workshop at Saint Louis University School of Law. In recent years, she was selected to present papers at conferences including “The Food and Drug Administration in the 21st Century”, sponsored by Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, “Conflicts of Interest in the Practice of Medicine: A National Symposium,” sponsored by the American Society of Law, Medicine & Ethics, and “Marketing Health: The Growing Role of Commercial Speech Doctrine in FDA Regulation,” sponsored by the American Journal of Law & Medicine.
Kate graduated magna cum laude from Georgetown University Law Center, where she served as an Articles Editor of the Georgetown Law Journal. She received her undergraduate degree in Economics from Swarthmore College. After law school, she spent two years as an Equal Justice Works Fellow and Staff Attorney at the Association of the Bar of the City of New York providing group instruction, technical assistance, and direct representation to indigent clients in family law and matrimonial matters. Following her fellowship, Kate served as a law clerk to federal judges at both the trial and appellate levels (Judge Mary A. McLaughlin of the U.S. District Court for the Eastern District of Pennsylvania and Judge Maryanne Trump Barry of the U.S. Court of Appeals for the Third Circuit). Before joining Seton Hall in 2008, Kate practiced law at Covington & Burling in New York, where she represented pharmaceutical companies, among other clients, in a variety of corporate, litigation, and white collar matters.
LAW REVIEW ARTICLES
Physician Conflicts of Interest in Court: Beyond the "Independent Physician" Litigation Heuristic, 30 Ga. St. U. L. Rev. 759 (2014)
The Ban on "Off-Label" Pharmaceutical Promotion: Constitutionally Permissible Prophylaxis against False or Misleading Commercial Speech?, 37 AM. J. L. & Med. 278 (2011) (symposium)
The Mysteries of Pregnancy: The Role of Law in Solving the Problem of Unknown but Knowable Maternal-Fetal Medication Risk, 79 U. Cin. L. Rev. 267 (2010)
OTHER JOURNAL ARTICLES
Toward Evidence-Based Conflicts of Interest Training for Physician-Investigators, J.L. Med. & Ethics, 500-507 (Fall 2012) (with Kathleen M. Boozang and Carl H. Coleman)
An Argument Against Embedding Conflicts of Interest Disclosures in Informed Consent, J. Health & Life Sci. L., 230-267 (June 2011) (with Kathleen M. Boozang and Carl H. Coleman)
New Jersey's Medicaid ACO Pilot Program, Past and Future: A Baseline Report, Seton Hall Center for Health & Pharmaceutical Law & Policy (2013) (co-authored with John Jacobi and Tara Adams Ragone)
Implementing the Essential Health Benefits Requirement in New Jersey: Decision Points and Policy Issues, policy brief issued by the Center for Health & Pharmaceutical Law & Policy & the Rutgers Center for State Health Policy (2012) (with John V. Jacobi and Tara Adams Ragone)
The Affordable Care Act’s Risk Adjustment and Other Risk-Spreading Mechanisms: Needed Support for New Jersey’s Health Insurance Exchange, policy brief issued by the Center for Health & Pharmaceutical Law & Policy and the Rutgers Center for State Health Policy (2012)
The Health Insurance Exchange, the Medicaid Program, and the Apportionment of Responsibility for Determining Eligibility and Effectuating Enrollment in New Jersey, policy brief issued by the Center for Health & Pharmaceutical Law & Policy and the Rutgers Center for State Health Policy (2012)
The Limits of Disclosure as a Response to Financial Conflicts of Interest in Clinical Research, white paper issued by the Center for Health & Pharmaceutical Law & Policy (2010) (collaborator)
Conflicts of Interest in Clinical Trial Recruitment & Enrollment: A Call for Increased Oversight, white paper issued by the Center for Health & Pharmaceutical Law & Policy (2009) (collaborator)
Drug and Device Promotion: Charting A Course for Policy Reform, white paper issued by the Center for Health & Pharmaceutical Law & Policy (2009) (collaborator)
The Alternate Approach to Medicinal Marijuana Distribution, The Record, O-1 (July 25, 2010)
Compliance Tips from Deferred Prosecution Agreements, Bus. Crimes Bull. (April 2006) (with Jacqueline C. Wolff)
The New SEC-FDA Alliance, Bus. Crimes Bull. (July 2004) (with Jacqueline C. Wolff)
Custodial Interrogations, 86 Geo. L.J. 1318 (1998) (with Jeffrey A. Brown)
Identifications, 86 Geo. L.J. 1309 (1998)
BOOKS AND BOOK CHAPTERS
Medical Affairs: Effectively and Legitimately Using Medical Science Liaisons, in Off-Label Communications: A Guide to Sales & Marketing Compliance (Food and Drug Law Institute 4th Ed. 2014) (with Deborah L. Shuff)